Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Predictions

buy
Sorrento Therapeutics Inc.

Start price
Target price
Perf. (%)
€4.97
27.12.21
€6.00
27.12.22
-83.85%
28.12.22

Could be worthwhile Investment >10% per year
buy
Fate Therapeutics Inc.

Start price
Target price
Perf. (%)
€20.67
26.10.22
€35.00
31.12.24
-41.33%
21.12.22

Could be very worthwhile Investment >20% year
buy
Aptose Biosciences

Start price
Target price
Perf. (%)
€0.98
14.12.21
-
14.12.22
-39.08%
15.12.22

Could be worthwhile Investment >10% per year
buy
Ardelyx Inc.

Start price
Target price
Perf. (%)
€1.29
08.09.22
€2.00
31.12.24
31.25%
09.12.22

Could be very worthwhile Investment >20% year
buy
ProQR Therapeutics N.V.

Start price
Target price
Perf. (%)
€0.81
07.09.22
€2.00
31.12.24
72.58%
09.12.22

Could be very worthwhile Investment >20% year
Karyopharm Therapeutics Inc.

Start price
Target price
Perf. (%)
€5.24
11.12.21
-
11.12.22
-16.73%
08.12.22

Risky Investment
Epizyme Inc.

Start price
Target price
Perf. (%)
€2.63
11.12.21
-
11.12.22
-45.63%
08.12.22

Probably not worthwhile Investment
Chimerix Inc.

Start price
Target price
Perf. (%)
€2.02
10.07.22
-
10.07.23
3.31%
08.12.22

Probably not worthwhile Investment
buy
Arbutus Biopharma Corp.

Start price
Target price
Perf. (%)
€4.85
01.12.21
-
01.12.22
-53.67%
02.12.22

Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
Stable Large shareholder and/or long term investor
Future proof or reliable business model
Acorda Therapeutics Cdt

Start price
Target price
Perf. (%)
€2.64
28.11.21
-
28.11.22
-77.46%
29.11.22

Risky Investment
buy
DBV Technologies S.A.

Start price
Target price
Perf. (%)
€5.24
27.11.21
€8.00
27.11.22
-47.90%
28.11.22

Could be worthwhile Investment >10% per year
buy
Onxeo S.A.

Start price
Target price
Perf. (%)
€0.41
27.11.21
€0.60
27.11.22
-56.65%
28.11.22

Could be worthwhile Investment >10% per year
buy
Drägerwerk AG & Co. KGaA VZO

Start price
Target price
Perf. (%)
€59.95
27.11.21
€75.00
27.11.22
-29.44%
28.11.22

Could be very worthwhile Investment >20% year
Few uniques
buy
MacroGenics Inc.

Start price
Target price
Perf. (%)
€6.85
17.11.22
-
17.11.23
-17.52%
27.11.22

Risky Investment
buy
Boiron S.A.

Start price
Target price
Perf. (%)
€38.05
26.11.21
-
26.11.22
18.79%
27.11.22

Could be worthwhile Investment >10% per year
buy
MacroGenics Inc.

Start price
Target price
Perf. (%)
€7.15
13.11.22
-
13.11.23
-20.98%
26.11.22

Could be worthwhile Investment >10% per year
buy
Valneva SE

Start price
Target price
Perf. (%)
€15.60
30.03.22
-
30.03.23
-55.74%
20.11.22

Could be worthwhile Investment >10% per year
Very valuable balance sheet
buy
Erytech Pharma S.A.

Start price
Target price
Perf. (%)
€2.24
19.11.21
€2.60
19.11.22
-69.80%
20.11.22

Could be worthwhile Investment >10% per year
buy
AB Science S.A.

Start price
Target price
Perf. (%)
€12.40
19.11.21
€13.60
19.11.22
-34.44%
20.11.22

Could be worthwhile Investment >10% per year
Arbutus Biopharma Corp.

Start price
Target price
Perf. (%)
€2.05
20.09.22
€1.80
20.09.23
36.59%
19.11.22

Differentiated customer and product portfolio
Lower EBIT Margin than peer group
High valuation
Very low/no dividend yield expected
buy
Acelrx Pharmaceuticals Inc.

Start price
Target price
Perf. (%)
€1.91
08.11.22
€4.20
08.11.23
23.85%
16.11.22

Axsome Therapeutics Inc

Start price
Target price
Perf. (%)
€32.27
16.11.21
€25.00
16.11.22
59.84%
16.11.22

Could be very worthwhile Investment >20% year
Curis Inc.

Start price
Target price
Perf. (%)
€5.06
14.11.21
-
14.11.22
-83.10%
15.11.22

Probably not worthwhile Investment
buy
Nanobiotix

Start price
Target price
Perf. (%)
€8.51
11.11.21
€10.00
11.11.22
-53.17%
12.11.22

Could be worthwhile Investment >10% per year
buy
Abeona Therapeutics Inc.

Start price
Target price
Perf. (%)
€3.62
03.11.22
-
03.11.23
13.26%
10.11.22

Could be very worthwhile Investment >20% year